Dr. Fabian Mohr

Senior Investment Manager

Dr. Fabian Mohr

Senior Investment Manager

Dr. Fabian Mohr holds a PhD in molecular medicine and supports the HTGF Life Science practice as investment manager. Before joining HTGF, Fabian was a project lead in strategy consulting for product innovation, data driven business models, M&A and evaluation of new technology use-cases in the Life Science and Medical Technology industry.

Contact

E-Mail:
f.mohr@htgf.de
Telefon:
+49 – (0)228 – 82300 – 181

Portfolio

Posts & mentions

Press
preomics logo
18. January 2022

PreOmics Announces Early Investors’ Exit and Closing of Series B Financing to Accelerate R&D and Commercialization of Proteomics Tools and Consumables

PreOmics Offers Unique Technologies, Advanced Automation Solutions and High-Performance Consumables for the Homogenization, Enrichment and Proteomic Sample Preparation of Biopsy, Tissue, Cell Line and Plasma Samples in Unbiased, Deep Proteomics for Pharmaceutical and Clinical Research MUNICH, Germany – January 18, 2022 – PreOmics GmbH, a Martinsried, Germany-based developer of innovative automation and sample preparation tools and consumables for unbiased, deep proteomics analysis
 
Press
Smarterials Founders
28. September 2021

MedTech startup Smarterials Technology closes second seed financing round

MedTech startup Smarterials Technology GmbH has successfully closed its second round of financing. Led by High-Tech Gründerfonds (HTGF), pre-seed investors Think.Health Ventures and Emanet also invest a total of nearly €1 million in the Berlin-based company. The new funding will be used to complete final development steps and prepare production for the mass market. Berlin, 28.09.2021 – Smarterials Technology develops surgical gloves based on innovative materials with a double barrier
 
Press
2. March 2021

Newly founded biotech company ActiTrexx receives funding of € 3.5 million to develop cell therapy against transplant rejection

ActiTrexx GmbH, a new biotech spin-off from the University Medical Center Mainz, Germany, has successfully closed its Series A financing. A consortium led by LBBW Venture Capital GmbH with participation from MediVentures GmbH, High-Tech Gründerfonds (HTGF) and Investitions- und Strukturbank Rheinland-Pfalz (ISB) invested a total of € 3.5 million. ActiTrexx develops ATreg, activated regulatory T cells (Tregs), which are stimulated using a proprietary process, to prevent rejection r